Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Estrada Guerrero, Andrea"'
Publikováno v:
In Urología Colombiana May-August 2016 25(2):146-153
Autor:
Quiroga Matamoros, William, Fernandez, Fernando, Citarella Otero, Danilo, Rangel, Jaime, Estrada Guerrero, Andrea, Patiño, Iván Darío
Publikováno v:
In Urología Colombiana May-August 2016 25(2):169-189
Publikováno v:
In Urología Colombiana May-August 2016 25(2):138-145
Publikováno v:
Urología Colombiana; May-August 2016, Vol. 25 Issue: 2 p138-145, 8p
Publikováno v:
1. Saman DM, Lemieux AM, Nawal Lutfiyya M, Lipsky MS. A review of the current epidemiology and treatment options for prostate cancer. Dis Mon. 2014 Apr;60(4):150–4.
2. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-289.
3. Pardo Ramos C, Cendales Duarte R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Bogotá: Ministerio de Salud y Protección Social : Instituto Nacional de Cancerología; 2015.
4. Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, et al. Prostate cancer. The Lancet. 2016 Jan;387(10013):70–82.
5. Popiolek M, Rider JR, Andrén O, Andersson S-O, Holmberg L, Adami H-O, et al. Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up. Eur Urol. 2013 Mar;63(3):428–35.
6. Andriole, M.D GL, Catalona, M.D WJ. Prostate Carcinoma. Annu Rev Med. 1994;45(1):351-359.
7. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013.
8. Washino S, Okochi T, Saito K, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU Int. 2017;119(2):225-233
9. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. Jama. 1993;270(7):860–4 10. Ismail MT, Gomella LG. Transrectal prostate biopsy. Urol Clin North Am. 2013;40(4):457-472.
11. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618–29
12. Chen N, Zhou Q. The evolving Gleason grading system. Chinese J Cancer Res. 2016;28(1):58-64
13. Andriole, M.D GL, Catalona, M.D WJ. Prostate Carcinoma. Annu Rev Med. 1994;45(1):351-359
14. Cam, K., Yucel S., Turkeri, L., Akdas, A. Accuracy of transrectal ultrasound guided prostate biopsy: histopathological correlation to matched prostatectomy specimens. Int J Urol. 2002;9(5):257-260
15. Pereira R, Costa R, Muglia V, et al. Gleason score and tumor laterality in radical prostatectomy and transrectal ultrasound-guided biopsy of the prostate: a comparative study. Asian J Androl. 2014;0(0):0
16. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: Accuracy and clinical implications. J Urol. 1997;157(2):559-562
17. Fernandes ET, Sundaram CP, Long R, Soltani M, Ercole CJ. Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? Br J Urol. 1997;79(4):615-617.
18. National Comprehensive Cancer Network Guidelines Version 4.2018 Prostate Cancer. Aug 15, 2018.
19. Luis J, Matiz P, Julián N, Reyes A, Paula M, Becerra S. Evolución de la mortalidad por cáncer de próstata en Colombia : estudio ecológico. 2014;23(1):3-10.
20. Ismail MT, Gomella LG. Transrectal prostate biopsy. Urol Clin North Am. 2013; 40(4):457-472.
21. Stamey T. Making the most out of six systematic biopsies. Urology. 1995; 45(1):2-12.
22. Litwin MS, Tan H-J. The Diagnosis and Treatment of Prostate Cancer. Jama. 2017;317(24):2532. doi:10.1001/jama.2017.7248.
23. D’Elia C, Cerruto M, Cioffi A, Novella G, Cavalleri S, Artibani W. Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy. Mol Clin Oncol. 2014:1145-1149.
24. Mills SE, Fowler JE. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer. 1986;57(2):346-349. http://www.ncbi.nlm.nih.gov/pubmed/3942967
25. Cohen MS, Hanley RS, Kurteva T, et al. Comparing the Gleason Prostate Biopsy and Gleason Prostatectomy Grading System: The Lahey Clinic Medical Center Experience and an International Meta-Analysis. Eur Urol. 2008;54(2):371-381. doi:10.1016/j.eururo.2008.03.049.
26. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades. Eur Urol. 2012;61(5):1019-1024. doi:10.1016/j.eururo.2012.01.050.
27. Kuroiwa K, Shiraishi T, Naito S. Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review. Urolo gy 2011;77:407–11.
28. Moussa AS, Li J, Soriano M, et al. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 2009;103:43–8.
29. Ruijter E, van Leenders G, Miller G, et al. Errors in histological grading by prostatic needle biopsy specimens: frequency and pre-disposing factors. J Pathol 2000;192: 229-33
30. Imamoto T, Suzuki H, Utsumi T, et al. External validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathol-ogy among Japanese patients. Urology 2010;76:404–10.
31. Capitanio U, Karakiewicz PI, Valiquette L, et al. Biopsy core number represents one of foremost predictors of clinically significant Glea-son sum upgrading in patients with low-risk prostate cancer. Urology 2009;73:1087–91.
32. Freedland SJ, Kane CJ, Amling CL, et al. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007;69:495–9.
2. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-289.
3. Pardo Ramos C, Cendales Duarte R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Bogotá: Ministerio de Salud y Protección Social : Instituto Nacional de Cancerología; 2015.
4. Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, et al. Prostate cancer. The Lancet. 2016 Jan;387(10013):70–82.
5. Popiolek M, Rider JR, Andrén O, Andersson S-O, Holmberg L, Adami H-O, et al. Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up. Eur Urol. 2013 Mar;63(3):428–35.
6. Andriole, M.D GL, Catalona, M.D WJ. Prostate Carcinoma. Annu Rev Med. 1994;45(1):351-359.
7. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013.
8. Washino S, Okochi T, Saito K, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU Int. 2017;119(2):225-233
9. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. Jama. 1993;270(7):860–4 10. Ismail MT, Gomella LG. Transrectal prostate biopsy. Urol Clin North Am. 2013;40(4):457-472.
11. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618–29
12. Chen N, Zhou Q. The evolving Gleason grading system. Chinese J Cancer Res. 2016;28(1):58-64
13. Andriole, M.D GL, Catalona, M.D WJ. Prostate Carcinoma. Annu Rev Med. 1994;45(1):351-359
14. Cam, K., Yucel S., Turkeri, L., Akdas, A. Accuracy of transrectal ultrasound guided prostate biopsy: histopathological correlation to matched prostatectomy specimens. Int J Urol. 2002;9(5):257-260
15. Pereira R, Costa R, Muglia V, et al. Gleason score and tumor laterality in radical prostatectomy and transrectal ultrasound-guided biopsy of the prostate: a comparative study. Asian J Androl. 2014;0(0):0
16. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: Accuracy and clinical implications. J Urol. 1997;157(2):559-562
17. Fernandes ET, Sundaram CP, Long R, Soltani M, Ercole CJ. Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? Br J Urol. 1997;79(4):615-617.
18. National Comprehensive Cancer Network Guidelines Version 4.2018 Prostate Cancer. Aug 15, 2018.
19. Luis J, Matiz P, Julián N, Reyes A, Paula M, Becerra S. Evolución de la mortalidad por cáncer de próstata en Colombia : estudio ecológico. 2014;23(1):3-10.
20. Ismail MT, Gomella LG. Transrectal prostate biopsy. Urol Clin North Am. 2013; 40(4):457-472.
21. Stamey T. Making the most out of six systematic biopsies. Urology. 1995; 45(1):2-12.
22. Litwin MS, Tan H-J. The Diagnosis and Treatment of Prostate Cancer. Jama. 2017;317(24):2532. doi:10.1001/jama.2017.7248.
23. D’Elia C, Cerruto M, Cioffi A, Novella G, Cavalleri S, Artibani W. Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy. Mol Clin Oncol. 2014:1145-1149.
24. Mills SE, Fowler JE. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer. 1986;57(2):346-349. http://www.ncbi.nlm.nih.gov/pubmed/3942967
25. Cohen MS, Hanley RS, Kurteva T, et al. Comparing the Gleason Prostate Biopsy and Gleason Prostatectomy Grading System: The Lahey Clinic Medical Center Experience and an International Meta-Analysis. Eur Urol. 2008;54(2):371-381. doi:10.1016/j.eururo.2008.03.049.
26. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades. Eur Urol. 2012;61(5):1019-1024. doi:10.1016/j.eururo.2012.01.050.
27. Kuroiwa K, Shiraishi T, Naito S. Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review. Urolo gy 2011;77:407–11.
28. Moussa AS, Li J, Soriano M, et al. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 2009;103:43–8.
29. Ruijter E, van Leenders G, Miller G, et al. Errors in histological grading by prostatic needle biopsy specimens: frequency and pre-disposing factors. J Pathol 2000;192: 229-33
30. Imamoto T, Suzuki H, Utsumi T, et al. External validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathol-ogy among Japanese patients. Urology 2010;76:404–10.
31. Capitanio U, Karakiewicz PI, Valiquette L, et al. Biopsy core number represents one of foremost predictors of clinically significant Glea-son sum upgrading in patients with low-risk prostate cancer. Urology 2009;73:1087–91.
32. Freedland SJ, Kane CJ, Amling CL, et al. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007;69:495–9.
El puntaje de Gleason como herramienta de estadificación histológica en pacientes con cáncer de próstata juega un papel de suma importancia en la determinación de pronóstico y comportamiento de la enfermedad por lo que es factor que debe ser te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2802::a1ef0ea71d9cd97e5c1833a0121ea963
https://hdl.handle.net/10654/21126
https://hdl.handle.net/10654/21126
